Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eli Lilly and Company

https://www.lilly.com/

Latest From Eli Lilly and Company

Obesity Gold Rush To Drive Significant Spending Growth Through Decade, IQVIA Says

IQVIA’s latest usage and spending trends report forecasts US obesity market will grow to $35bn by 2028, while the two leading GLP-1 agonists have already posted eye-popping sales growth.

Pricing Debate Metabolic Disorders

Project 5 In 5: US FDA Oncology Office Seeks Pragmatic Trial Proposals From Clinicians, Patients

Industry has been slow to embrace the idea of pragmatic clinical trials with streamlined data collection, so the Oncology Center of Excellence now is turning to the broader cancer community for research proposals.

Clinical Trials Post Market Regulation & Studies

Hanmi Eyes Digital Healthcare As Next Growth Engine

Hanmi’s head of new product development elucidated the leading Korean pharma firm’s digital healthcare strategy at a recent domestic forum, including plans for the country’s first medicine/DTx combo, and shared views on what is needed to improve the domestic regulatory and market environment.

South Korea Digital Health

Synthetic Biology Matures, Promising Affordable And Personalized Treatments

Advances in synthetic biology are moving biopharma closer to a world where treatments can be tailored while remaining cost-effective.

Innovation Artificial Intelligence
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Akouos, Inc.
    • Alnara Pharmaceuticals, Inc.
    • ARMO BioSciences, Inc.
    • Applied Molecular Evolution
    • Avid Radiopharmaceuticals, Inc.
    • Bowfin Acquisition Corporation
    • Class AP
    • CoLucid Pharmaceuticals, Inc.
    • Dermira Inc.
    • Disarm Therapeutics, Inc.
    • Hypnion
    • ICOS Corporation
    • ImClone Systems
    • Loxo Oncology, Inc. (LOXO)
    • Protomer Technologies
    • SGX Pharmaceuticals (Structural GenomiX)
    • Valocor Therapeutics, Inc.
UsernamePublicRestriction

Register